Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up
Open Access
- 5 November 2021
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 1978